Format

Send to

Choose Destination
Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Author information

1
Cancer Genomics and Genetics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 8006, Australia; and the Kinghorn Cancer Centre, Garvan Institute for Medical Research, Darlinghurst, Sydney, 2010 New South Wales, Australia.
2
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
3
Nuffield Department of Obstetrics and Gynaecology and the Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK.
4
Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
5
MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
6
University of Oxford, Headington, Oxford, OX3 7LF, UK.
7
Stanford University, Stanford, California 94305, USA.
8
Massachusetts General Hospital, Boston, Massachusetts 02114 USA.
9
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
10
Arizona Oncology, Tucson, Arizona 85711, USA.
11
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
12
The Sidney Kimmel Cancer Center at John Hopkins University, Baltimore, Maryland 21287, USA.
13
University Hospital of Lausanne, Lausanne, Switzerland.
14
University of Pennsylvania, Penn Ovarian Cancer Research Center, Philadelphia, Pennsylvania 19104, USA.
15
University of Manchester, Manchester M13 9WL, UK.
16
Institut National de la Santé et de la Recherche Médicale, UMRS1138, Laboratory of Integrative Cancer Immunology, Cordeliers Research Center, Université Paris Descartes, Sorbonne Paris Cité, Sorbonne Universités, UPMC Univ Paris 06, 75006 Paris, France.
17
Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK.
18
Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.
19
University of British Columbia, Departments of Pathology and Laboratory Medicine and Obstetrics and Gynecology, Faculty of Medicine, Vancouver, British Columbia V6T 2B5, Canada.
20
Harvard Medical School, Boston, Massachusetts 02115, USA.
21
Ovarian Cancer Action, London NW1 OJH, UK.
22
University of Chicago, Chicago, Illinois 60637, USA.
23
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
24
University of Glasgow, Glasgow G61 1QH, UK.
25
Women's Cancer, Institute for Women's Health, University College London, London WC1E 6BT, UK.
26
Women's College Research Institute, Toronto, Ontario M5G 1N8, Canada.
27
British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, Canada.
28
Indiana University School of Medicine &Simon Cancer Center, Bloomington, IN 47405-4401, USA.
29
University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
30
University of Pennsylvania, Philadelphia, PA 19104-5156, USA.
31
Translational Genomics Research Institute (Tgen), Phoenix, Arizona 85004, USA.

Abstract

High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

PMID:
26493647
PMCID:
PMC4892184
DOI:
10.1038/nrc4019
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center